T hrough its Priority Review mechanism, the U.S. Food and Drug Administration (FDA) recently approved 2 radiopharmaceutical products for use as diagnostic PET agents. The first, approved on May 27, was Axumin (18F-fluciclovine) injection, indicated for use in PET imaging to identify suspected sites of prostate cancer recurrence in men with elevated levels of prostate-specific antigen (PSA) foll...